WO2014167582A3 - Vaccine composition for prophylaxis in ruminants - Google Patents

Vaccine composition for prophylaxis in ruminants Download PDF

Info

Publication number
WO2014167582A3
WO2014167582A3 PCT/IN2014/000204 IN2014000204W WO2014167582A3 WO 2014167582 A3 WO2014167582 A3 WO 2014167582A3 IN 2014000204 W IN2014000204 W IN 2014000204W WO 2014167582 A3 WO2014167582 A3 WO 2014167582A3
Authority
WO
WIPO (PCT)
Prior art keywords
bluetongue
ruminants
prophylaxis
vaccine composition
vaccine
Prior art date
Application number
PCT/IN2014/000204
Other languages
French (fr)
Other versions
WO2014167582A2 (en
Inventor
Pavuluri Panduranga RAO
Nagendra Ramachandra HEGDE
Original Assignee
Ella Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ella Foundation filed Critical Ella Foundation
Publication of WO2014167582A2 publication Critical patent/WO2014167582A2/en
Publication of WO2014167582A3 publication Critical patent/WO2014167582A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12161—Methods of inactivation or attenuation
    • C12N2720/12163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses vaccine compositions against Bluetongue serotype 12 and preparation of vaccine for Bluetongue in suspension cells. Further, the invention relates to a preventive vaccine for Bluetongue disease or infection caused by bluetongue virus serotype 12 (BTV-12) in ruminants. Methods of inactivation of Bluetongue virus are also disclosed.
PCT/IN2014/000204 2013-03-31 2014-04-01 Vaccine composition for prophylaxis in ruminants WO2014167582A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1268/CHE/2013 2013-03-31
IN1268CH2013 2013-03-31

Publications (2)

Publication Number Publication Date
WO2014167582A2 WO2014167582A2 (en) 2014-10-16
WO2014167582A3 true WO2014167582A3 (en) 2014-12-24

Family

ID=51690090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000204 WO2014167582A2 (en) 2013-03-31 2014-04-01 Vaccine composition for prophylaxis in ruminants

Country Status (1)

Country Link
WO (1) WO2014167582A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170247665A1 (en) * 2014-08-29 2017-08-31 Biovet Private Limited A bluetongue vaccine and methods of manufacture thereof
CN109200282A (en) * 2018-11-23 2019-01-15 中国兽医药品监察所 A kind of sheep pox inactivated vaccine and its production method
CN112870346A (en) * 2021-01-21 2021-06-01 云南省畜牧兽医科学院 Preparation method of bluetongue virus bivalent inactivated vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065930A1 (en) * 2007-11-21 2009-05-28 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
WO2009128043A1 (en) * 2008-04-16 2009-10-22 Onderstepoort Biological Products Ltd Inactivated live-attenuated bluetongue virus vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065930A1 (en) * 2007-11-21 2009-05-28 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
WO2009128043A1 (en) * 2008-04-16 2009-10-22 Onderstepoort Biological Products Ltd Inactivated live-attenuated bluetongue virus vaccine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BROWN ET AL.: "The Effect of Various Inactivating Agents on the Viral and Ribonucleic Acid Infectivities of Foot-and-Mouth Disease Virus and on its Attachment to Susceptible Cells", J . GEN. MICROBIAL., vol. 31, 1963, pages 179 - 186 *
HATA ATSUKO ET AL.: "Use of an inactivated varicella vaccine in recipients of hematopoieticcell transplants.", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 347, no. 1, 4 July 2002 (2002-07-04), pages 26 - 34 *
MARTIN JAVIER ET AL.: "Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR. GENERAL MICROBIOLOGY, vol. 84, no. 7, 1 July 2003 (2003-07-01), GB, pages 1781 - 1788 *
MATTION N ET AL.: "Reintroduction of foot-and-mouth disease in Argentina : characterisation of the isolates and development of tools for the control and eradication of the disease", VACCINE, vol. 22, no. 31-32, 22 October 2004 (2004-10-22), GUILDFORD, GB, pages 4149 - 4162 *
NARENDER S. MAAN ET AL.: "Identification and Differentiation of the Twenty Six Bluetongue Virus Serotypes by RT-PCR Amplification of the Serotype-Specific Genome Segment 2", PLOS ONE, vol. 7, no. 2, 28 February 2012 (2012-02-28), pages 1 - 9 *
ODEON A C ET AL.: "The role of cell -mediated immunity in the pathogenesis of bluetongue virus serotype 11 in the experimental infection of vaccine/sensitized calves.", COMPARATIVE IMMUNOLOGY, MICROBIOLOGY AND INFECTIOUS DISEASES JUN 1997, vol. 20, no. 3, June 1997 (1997-06-01), pages 219 - 231 *
RAMAKRISHNAN M A ET AL.: "Immune Responses and Protective Efficacy of Binary Ethylenimine (BEI)-Inactivated Bluetongue Virus Vaccines in Sheep", VETERINARY RESEARCH COMMUNICATIONS ; AN INTERNATIONAL JOURNAL PUBLISHING TOPICAL REVIEWS AND RESEARCH ARTICLES ON ALL ASPECTS OF THE VETERINARY SCIENCES, vol. 30, no. 8, 1 November 2006 (2006-11-01), pages 873 - 880 *
SAVIN I G ET AL.: "An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy .", VETERINARY MICROBIOLOGY, vol. 124, no. 1-2, 20 September 2007 (2007-09-20), pages 140 - 146 *
SAVINI ET AL.: "Vaccines against bluetongue in Europe", COMPARATIVE IMMUNOLOGY, MICROBIOLOGY AND INFECTIOUS DISEASES, vol. 31, no. 2-3, 1 March 2008 (2008-03-01), OXFORD, GB, pages 101 - 120 *

Also Published As

Publication number Publication date
WO2014167582A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
WO2017100726A8 (en) Methods for treating huntington's disease
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2017070626A3 (en) Respiratory virus vaccines
PH12016501122A1 (en) Delayed release compositions of linaclotide
CA2917096C (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
IN2015DN03327A (en)
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PH12016501968A1 (en) Novel macrocyclic compounds
MX2020002123A (en) Ribociclib salts and solid state forms thereof.
MX2013012233A (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines.
PH12015502747A1 (en) Novel compounds for the treatment of cancer
EP4241851A3 (en) Immunogenic compositions
MX2017004760A (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof.
EP3057611A4 (en) Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
WO2016119052A8 (en) Compositions and methods for enhancing oncolytic virus efficacy
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
EP3292872A4 (en) Composition for treatment or prevention of infectious inflammatory disease, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as active ingredient
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14783518

Country of ref document: EP

Kind code of ref document: A2